Compare AbCellera Biologics Inc (ABCL) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? AbCellera Biologics Inc trades at $10.32 (market cap $2.99B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ABCL | YMAX | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $9.76 | $13.26 |
52-Week Low | $2.78 | $7.27 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
YMAX trades at $7.63, down 1.04% in the past 24 hours, with technical indicators showing a bullish overall signal but bearish moving averages. The fund has announced consistent weekly dividend distributions, though recent news highlights concerns over fee structures impacting payouts. Key support is at $7, with resistance at $8.
The outlook for YMAX hinges on its ability to sustain dividend yields amid fee pressures; opportunities include high income generation, but risks involve cost inefficiencies and market volatility. Analyst sentiment is mixed, balancing yield appeal against structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
